Loading data
PRGONYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.25 bn USD | 4.37 bn USD | 4.66 bn USD | 4.45 bn USD | 4.14 bn USD |
| Cost of revenue | 2.76 bn USD | 2.83 bn USD | 2.98 bn USD | 3 bn USD | 2.72 bn USD |
| Gross profit | 1.49 bn USD | 1.54 bn USD | 1.68 bn USD | 1.46 bn USD | 1.42 bn USD |
| Research and development expense | 95.4 m USD | 112.2 m USD | 122.5 m USD | 123.1 m USD | 122 m USD |
| Operating profit | -1.12 bn USD | 112.9 m USD | 151.9 m USD | 78.9 m USD | 410.4 m USD |
| Profit before tax | -1.3 bn USD | -80.7 m USD | -8.3 m USD | -139.1 m USD | 258.7 m USD |
| Income tax expense | 104.4 m USD | 80 m USD | -3.9 m USD | -8.2 m USD | 389.6 m USD |
| Net income (reported basis) | -1.43 bn USD | -172 m USD | -13 m USD | -141 m USD | -69 m USD |
| Basic earnings per share | -10.29 USD/share | -1.25 USD/share | -0.09 USD/share | -1.04 USD/share | -0.52 USD/share |
| Diluted earnings per share | -10.29 USD/share | -1.25 USD/share | -0.09 USD/share | -1.04 USD/share | -0.52 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.